Zacks Investment Research upgraded shares of BIOLINERX Ltd/S (NASDAQ:BLRX) from a sell rating to a hold rating in a research report released on Wednesday.
According to Zacks, “Bioline RX Ltd. is a biopharmaceutical development company. BioLineRx is dedicated to building a portfolio of products for unmet medical needs or with advantages over currently available therapies. The Company’s portfolio consists of clinical stage candidates including BL-1020 for schizophrenia , BL-1040, for treatment of patients following a myocardial infarction, BL-5010 for non-surgical removal of skin lesions, BL-1021 for neuropathic pain and BL-7040 for treating Inflammatory Bowel Disease. In addition, BioLineRx has many products in various pre-clinical development stages for a variety of indications, including central nervous system diseases, oncology, infectious diseases, cardiovascular and autoimmune diseases. “
A number of other equities analysts also recently commented on the stock. HC Wainwright set a $4.00 price objective on shares of BIOLINERX Ltd/S and gave the stock a buy rating in a report on Wednesday, October 3rd. ValuEngine raised shares of BIOLINERX Ltd/S from a hold rating to a buy rating in a report on Thursday, October 4th. Maxim Group reaffirmed a buy rating and issued a $2.00 price objective on shares of BIOLINERX Ltd/S in a report on Monday, August 13th. Finally, MED initiated coverage on shares of BIOLINERX Ltd/S in a report on Wednesday, August 1st. They issued a market perform rating for the company. Two analysts have rated the stock with a hold rating and four have issued a buy rating to the company. The company presently has an average rating of Buy and a consensus price target of $2.50.
BIOLINERX Ltd/S stock traded down $0.01 during mid-day trading on Wednesday, reaching $0.70. The company’s stock had a trading volume of 391,694 shares, compared to its average volume of 1,728,884. The company has a market cap of $78.77 million, a PE ratio of -2.59 and a beta of 0.87. BIOLINERX Ltd/S has a twelve month low of $0.67 and a twelve month high of $1.84.
BIOLINERX Ltd/S (NASDAQ:BLRX) last released its quarterly earnings data on Thursday, November 8th. The biotechnology company reported ($0.06) EPS for the quarter, hitting analysts’ consensus estimates of ($0.06). On average, research analysts predict that BIOLINERX Ltd/S will post -0.22 EPS for the current year.
A hedge fund recently bought a new stake in BIOLINERX Ltd/S stock. Fosun International Ltd purchased a new stake in shares of BIOLINERX Ltd/S (NASDAQ:BLRX) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 1,357,415 shares of the biotechnology company’s stock, valued at approximately $1,412,000. Fosun International Ltd owned 1.27% of BIOLINERX Ltd/S as of its most recent filing with the Securities and Exchange Commission (SEC). Hedge funds and other institutional investors own 34.69% of the company’s stock.
About BIOLINERX Ltd/S
BioLineRx Ltd., a clinical stage biopharmaceutical development company focused on oncology and immunology. Its development pipeline consists of clinical-stage therapeutic candidates, which include BL-8040, a peptide for the treatment of multiple cancer and hematological indications; AGI-134, an immuno-oncology agent in development for solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of benign skin lesions.
Further Reading: What does relative strength index mean?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for BIOLINERX Ltd/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BIOLINERX Ltd/S and related companies with MarketBeat.com's FREE daily email newsletter.